Results 141 to 150 of about 53,753 (240)

Systematic profiling reveals broad G protein coupling and context‐dependent modulation of cyclic AMP by the orphan receptor GPR139

British Journal of Pharmacology, EarlyView.
Background and Purpose G protein‐coupled receptors (GPCRs) are major drug targets, yet many orphan receptors remain poorly characterized. GPR139 has been implicated in CNS disorders, including schizophrenia and depression, but its signalling mechanisms remain unclear.
Boris Trapkov, Hans Bräuner, Alexander Sebastian Hauser   +2 more
wiley   +1 more source

Transcriptomic Analysis Identifies <i>CDKN2A</i>-Associated Transcriptional Alterations in Primary Melanocytes of Lueyang Black-Boned Chicken. [PDF]

Animals (Basel)
Li F, Cao Z, Zhang Q, Han W, Yang L, Song J, Xue Q, Jin K.   +7 more
europepmc   +1 more source

Pleiotropic Roles of FBXO11 in Tumorigenesis: Implications for Targeted Therapy

Cancer Science, EarlyView.
This complex comprises of scaffold CUL1, SKP1, RBX1 and FBXO11 receptor. The substrate is phosphorylated by specific kinase enzyme and recognized by the substrate recognition domain. FBXO11 targets numerous substrates for ubiquitination and degradation, FBXO11 substrates mainly include Snail, ZEB1, p53, BCL6, CDT2, CIITA, Cdc25a, hnRNPA2B1, SAMD1 and ...
Yuqi Zhang, Changyi Fan, Shiheng Chen, Tianyue Lu, Yuanyuan Li, Feng Du, Shanshan Wang   +6 more
wiley   +1 more source

GNAQ Induces Melanomagenesis in Mitfa-Independent Melanocyte Progenitors in a Zebrafish Model of Uveal Melanoma. [PDF]

Cancer Res
Yevdash JI, Robinson D, Moore R, Li Z, Campbell-Hanson KR, Gutelius D, Moore SPG, Friend D, O'Toole I, Harman BE, Montgomery C, Cornell RA, Birbrair A, Riordan JD, Dupuy AJ, Binkley EM, Mullins RF, Lang D, Weigel RJ, Kenny C.   +19 more
europepmc   +1 more source

Current Approaches to Support Patients to Withdraw From Image and Performance Enhancing Drugs

Clinical Endocrinology, EarlyView.
ABSTRACT Image and performance‐enhancing drugs (IPEDs) include agents such as androgens, growth hormone, and erythropoietin, which are used to enhance appearance and physical performance. Androgens, also known as anabolic‐androgenic steroids (AAS), are the most used IPEDs worldwide.
Elizabeth Hyams, Bonnie Grant, Richard Quinton, Channa N. Jayasena   +3 more
wiley   +1 more source

Infrared radiation alleviates damage to epidermal melanocytes induced by ultraviolet irradiation: potential for improving the efficacy of phototherapy for vitiligo lesions. [PDF]

Front Bioeng Biotechnol
Bao HY, Jin R, Wu F, Shao X, Tan ZL, Xu A.   +5 more
europepmc   +1 more source

Dermatologic Toxicities Associated With Novel Pan‐RAS/RAF Inhibitors

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Background The mitogen‐activated protein kinase (MAPK) pathway plays a key role in cell‐cycle regulation and tumor progression in cancer. Dermatologic toxicities (DTs) to newer pan‐RAS (RMC‐6236) and pan‐RAF (LXH254/naporafenib) inhibitors are emerging.
Lin J. He, Shaymaa Hegazy, Phyu P. Aung, Priyadharsini Nagarajan, Fiorinda Muhaj, Adrienne N. Choksi, Ana M. Ciurea, Kelly C. Nelson, Doina Ivan, Carlos A. Torres‐ Cabala, Victor G. Prieto, Jonathan L. Curry   +11 more
wiley   +1 more source

Vitiligo-Current Treatment Options and Future Perspectives. [PDF]

Int J Mol Sci
Wojno A, Wojno A, Karwowska A, Chmielewska M, Maj J, Łyko M.   +5 more
europepmc   +1 more source

Diagnostic Utility of PRAME Immunohistochemistry for Distinguishing Acral Melanoma From Acral Melanocytic Nevi

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Introduction Preferentially expressed antigen in melanoma (PRAME) immunohistochemistry helps distinguish non‐acral melanocytic lesions, but few studies have addressed its value in acral lesions. We aimed to identify an optimal PRAME cut‐off score to differentiate acral melanoma (AM) from acral melanocytic nevi (AMN).
Kritsada Phatcharamaneepakorn, Panitta Sitthinamsuwan, Penvadee Pattanaprichakul, Manasmon Chairatchaneeboon, Nutcha Yodrabum   +4 more
wiley   +1 more source

Early-Onset Vogt-Koyanagi-Harada-Like Syndrome After Combined Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report. [PDF]

Cureus
Etheve F, Hainaut E, Boutin D, Riviere R.   +3 more
europepmc   +1 more source